Canada markets closed

Cardinal Health, Inc. (CLH.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
103.65+0.80 (+0.78%)
At close: 08:01AM CET
Full screen
Previous Close102.85
Open103.65
Bid103.35 x 20000
Ask104.15 x 20000
Day's Range103.65 - 103.65
52 Week Range68.80 - 106.30
Volume35
Avg. Volume32
Market Cap25.211B
Beta (5Y Monthly)0.69
PE Ratio (TTM)44.48
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.85 (1.79%)
Ex-Dividend DateMar 28, 2024
1y Target EstN/A
  • PR Newswire

    Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2024 on May 2

    Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.

  • PR Newswire

    Cardinal Health announces approved science-based climate targets; expands focus across the supply chain

    Cardinal Health (NYSE: CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions reduction targets. Targets are considered science-based if they align with what the latest climate science says is necessary to limit global warming to 1.5°C above pre-industrial levels.

  • PR Newswire

    Cardinal Health annual research report examines milestone year in biosimilars

    Today, Cardinal Health (NYSE: CAH) released its 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, an analysis of key recent economic, competitive, legislative and societal developments in biosimilars. The publication highlights legislative developments and new treatments, including adalimumab biosimilars. The report also provides the perspectives of retina specialists on biosimilars, ahead of the expected launch of multiple new biosimilars for retinal diseases.